Major involvement of mTOR in the PPAR gamma-induced stimulation of adipose tissue lipid uptake and fat accretion
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
30/10/2013
30/10/2013
2012
|
Resumo |
Evidence points to a role of the mammalian target of rapamycin (mTOR) signaling pathway as a regulator of adiposity, yet its involvement as a mediator of the positive actions of peroxisome proliferator-activated receptor (PPAR)gamma agonism on lipemia, fat accretion, lipid uptake, and its major determinant lipoprotein lipase (LPL) remains to be elucidated. Herein we evaluated the plasma lipid profile, triacylglycerol (TAG) secretion rates, and adipose tissue LPL-dependent lipid uptake, LPL expression/activity, and expression profile of other lipid metabolism genes in rats treated with the PPAR gamma agonist rosiglitazone (15 mg/kg/day) in combination or not with the mTOR inhibitor rapamycin (2 mg/kg/day) for 15 days. Rosiglitazone stimulated adipose tissue mTOR complex 1 and AMPK and induced TAG-derived lipid uptake (136%), LPL mRNA/activity (2- to 6-fold), and fat accretion in subcutaneous (but not visceral) white adipose tissue (WAT; 50%) and in brown adipose tissue (BAT; 266%). Chronic mTOR inhibition attenuated the upregulation of lipid uptake, LPL expression/activity, and fat accretion induced by PPAR gamma activation in both subcutaneous WAT and BAT, which resulted in hyperlipidemia. In contrast, rapamycin did not affect most of the other WAT lipogenic genes upregulated by rosiglitazone. Together these findings demonstrate that mTOR is a major regulator of adipose tissue LPL-mediated lipid uptake and a critical mediator of the hypolipidemic and lipogenic actions of PPAR gamma activation.-Blanchard, P-G., W. T. Festuccia, V. P. Houde, P. St-Pierre, S. Brule, V. Turcotte, M. Cote, K. Bellmann, A. Marette, and Y. Deshaies. Major involvement of mTOR in the PPAR gamma-induced stimulation of adipose tissue lipid uptake and fat accretion. J. Lipid Res. 2012. 53: 1117-1125. Canadian Institutes of Health Research (CIHR) [36451, 144336] Canadian Institutes of Health Research (CIHR) Natural Sciences and Engineering Research Council of Canada (NSERC) [36-2011] Natural Sciences and Engineering Research Council of Canada (NSERC) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/15354-7, 10/10909-8] Agence universitaire de la francophonie (AUF)FAPESP Agence universitaire de la francophonie (AUF)-FAPESP Fonds de la recherche en sante du Quebec (FRSQ) Fonds de la Recherche en Sante du Quebec (FRSQ) |
Identificador |
JOURNAL OF LIPID RESEARCH, BETHESDA, v. 53, n. 6, supl. 1, Part 3, pp. 1117-1125, JUN, 2012 0022-2275 http://www.producao.usp.br/handle/BDPI/36939 10.1194/jlr.M021485 |
Idioma(s) |
eng |
Publicador |
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC BETHESDA |
Relação |
JOURNAL OF LIPID RESEARCH |
Direitos |
restrictedAccess Copyright AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC |
Palavras-Chave | #MAMMALIAN TARGET OF RAPAMYCIN #DYSLIPIDEMIA #LIPOPROTEIN LIPASE #TRIGLYCERIDES #ADIPOSE TISSUE #OBESITY #PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR #LIPOPROTEIN-LIPASE ACTIVITY #ADIPONECTIN RECEPTORS #AGONIST ROSIGLITAZONE #GLUCOSE-UPTAKE #RAPAMYCIN #METABOLISM #RAT #CELL #SIROLIMUS #MICE #BIOCHEMISTRY & MOLECULAR BIOLOGY |
Tipo |
article original article publishedVersion |